Federation Des Caisses Desjardins Du Quebec Kura Oncology, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 30, 2024	SELL	$14.71 - $19.79 $2,471 - $3,324	-168 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$10.6 - $17.49 $1,780 - $2,938	168 New	168 $2.36 Million
Q1 2018 Aug 30, 2024	BUY	$14.5 - $23.4 $2,436 - $3,931	168 New	168 $3.15 Million

Others Institutions Holding KURA

# of Institutions

187

Shares Held

81.9M

Call Options Held

42.1K

Put Options Held

34K

Suvretta Capital Management, LLC New York, NY

7.65M
Shares

$60.5 Million
5.88% of portfolio
Black Rock Inc. New York, NY

6.97M
Shares

$55.1 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

5.81M
Shares

$45.9 Million
4.92% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

5.41M
Shares

$42.8 Million
1.97% of portfolio
Paradigm Biocapital Advisors LP New York, NY

4.33M
Shares

$34.3 Million
3.05% of portfolio

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $529M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account